Home / Asia-Pacific / Singapore / Life Sciences & Healthcare

Life Sciences & Healthcare

As part of a global team with over 480 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your lifesciences business. We work with and have established long-term relationships with the top 100 lifesciences companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.


Feed

15/04/2024
Top developments and predictions in the Life Sciences & Healthcare sector...
In this round-up, we look back at the top developments over the last 12 months in the life sciences & healthcare (LSHC) sector, and we look to the future with our top predictions for the coming year for...
18/12/2023
Digital health apps and telemedicine in Singapore
Digital Health Apps/Software 1. How is the software within digital health apps classified in your jurisdiction, and what regulation(s) apply? 1.1 Is it considered a “medical device” or a “product”...
Comparable
08/12/2023
COP28: Global Health Under the Spotlight
Health took centre stage at the first ever ‘Health Day’ at COP28 on 3 December. The program focused the attention of world leaders on the profound public health-related issues stemming from climate...
26/04/2023
Top developments and predictions in the Life Sciences & Healthcare sector...
In this round-up, we look back at the top developments over the last 12 months in the life sciences & healthcare sector, and we look to the future with our top predictions for the coming year for businesses...
08/03/2023
Out with the old, in with the new? Procedural features of the Unified Patent...
In our previous article, we looked at the current European system of patent prosecution and enforcement and highlighted some of the key changes that will be coming with the new Unitary Patent and Unified...
02/11/2022
APAC IP Update – Autumn 2022
China CNIPA releases China Patent Survey Report 2021 In July 2022, the China National Intellectual Property Administratiion (CNIPA) released the China Patent Survey Report 2021. The data in the report...
07/06/2022
Trade secret laws and regulations in Singapore
General 1. Has the Directive (EU) 2016/943 of the European Parliament and of the Council of 8 June 2016 on the protection of undisclosed know-how and business information (trade secrets) against their...
Comparable
07/06/2022
Adverse effects of drugs and vaccines in Singapore
1. Drug adverse effects: kinds of responsibility 1.1 Which are the main kinds of responsibility (contractual, in tort, criminal) of the following subjects with respect to adverse drugs reactions? For...
Comparable
01/06/2022
CMS Next
What’s next? In a world of ever-ac­cel­er­at­ing change, staying ahead of the curve and knowing what’s next for your business or sector is essential. At CMS, we see ourselves not only as your legal advisers but also as your business partners. We work together with you to not only resolve current issues but to anticipate future challenges and innovate to meet them. With our latest publication, CMS Next, our experts will regularly offer you insights into and fresh perspectives on a range of issues that businesses have to deal with – from ESG agendas to restructuring after the pandemic or facing the digital transformation. We will also share with you more about the work that we are doing for our clients, helping them innovate, grow and mitigate risk. To be able to provide you with the best support, we immerse ourselves in your world to understand your legal needs and challenges. However, it is equally important that you know who we are and how we can work with you. So, we invite you to meet our experts and catch a glimpse of what is happening inside CMS. Enjoy reading this publication, which we will update regularly with new content. CMS Executive Team
16/03/2022
APAC IP Update – Winter 2021-2022
China CNIPA releases the Amended Measures for Registration of Pledge of Patent Rights On 16 November 2021, the China National Intellectual Property Administration (CNIPA) released the amended “Measures...
21/12/2021
APAC IP Update – Winter 2021
China China encourages IP disputes mediation On 22 October 2021, the China National Intellectual Property Administration (CNIPA) and the Ministry of Justice jointly issued “the Opinions on Strengthening...
26/11/2021
CMS On the Pulse episode #10:  Digital Health law, regulations and developments...
The Global Life Sciences & Healthcare Sector Group, along with the Lifesciences Asia-Pacific Network (LAN), are delighted to release the latest episode in its video/podcast series, On the Pulse. The series...